Loading stock data…
MBX
$29.78-0.44 (-1.46%)
Market ClosedLast close May 1
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MBX Biosciences, Inc. in the Healthcare sector is trading at $29.78. The stock is currently 34% below its 52-week high of $44.89, remaining 18.0% above its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why MBX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.78
Potential Upside
5%
Whystock Fair Value$31.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$62.55+110.0%
Range$20.00 – $88.00
Fundamentals
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109),...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.86%
Volume
Today's trading volume
433,450
Recent News
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase
MBX Biosciences targets endocrine and metabolic disorders with novel peptide therapies, advancing candidates across several clinical phases.
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative?
In recent days, MBX Biosciences has attracted attention as its shares reacted to a technical breakout supported by heavy options trading and fresh analyst coverage, while the company also issued a stock option inducement grant to its new Chief Business Officer, Karen Basbaum. The combination of chart-driven momentum, bullish options positioning, and renewed analyst interest highlights how sentiment and trading behavior can move the stock without any major change to MBX Biosciences’...
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp stock gains.
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus
MBX Biosciences (NasdaqGS:MBX) completed a successful End-of-Phase 2 meeting with the FDA for its lead candidate canvuparatide in chronic hypoparathyroidism. The company secured orphan drug designation for canvuparatide from the European Medicines Agency. MBX announced plans to advance canvuparatide into a pivotal Phase 3 trial. MBX appointed experienced biopharma executive Karen Basbaum as Chief Business Officer, expanding its leadership team. MBX Biosciences focuses on therapies for...
MBX Biosciences CFO Shift Puts Funding And Execution In Focus
MBX Biosciences (NasdaqGS:MBX) announced the resignation of Chief Financial Officer Richard Bartram. The company appointed John Smither as Interim CFO, effective upon Bartram’s departure. Smither brings extensive prior CFO and board experience in the biopharma sector to the interim role. For a company like MBX Biosciences, which is focused on developing therapies in the biopharma space, a change at the CFO level sits at the core of how it manages cash, partnerships, and future funding...